ICU MEDICAL ALERT: Kaplan Fox & Kilsheimer LLP is Investigating ICU Medical, Inc. (ICUI) for Potential Securities Law Violations
NEW YORK, NY - May 1, 2025 ( NEWMEDIAWIRE ) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against ICU Medical, Inc. ('ICU Medical' or the 'Company') (NASDAQ: ICUI).
CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION
If you are an ICU Medical investor and have suffered losses, you may CLICK HERE to contact us. You may also contact Kaplan Fox by emailing [email protected] or by calling (646) 315-9003.
On April 22, 2025, Bloomberg reported that the Federal Drug Administration ('FDA') had issued a Warning Letter to ICU Medical 'regarding unapproved changes to its infusion pumps.' The Warning Letter, dated April 4, 2025, which was based on an FDA inspection from July 23 through August 9, 2024, states that the Company 'made multiple changes to the Medfusion(R) Model 4000 Syringe Infusion Pump and CADD(R) Solis VIP Ambulatory Infusion Pump that could significantly affect the safety or effectiveness of these devices,' and that the Company 'failed to submit a premarket notification submission to [the] FDA for significant changes or modifications that could significantly affect the safety or effectiveness of these devices. . . .' The Warning Letter further states that the pumps are 'adulterated . . . because [the Company] does not . . . have an approved application for premarket approval (PMA) in effect.'
Following this news, the price of ICU Medical stock declined by as much as $10.72 per share, or by approximately 8%, during intraday trading. On April 22, 2025, ICU shares closed at $130.68 per share, a decline of $6.04 per share, or over 4%, from the closing price the prior day.
WHY CONTACT KAPLAN FOX - Kaplan Fox is a leading national law firm focusing on complex litigation with offices in New York, Oakland, Los Angeles, Chicago and New Jersey. With over 50 years of experience in securities litigation, Kaplan Fox offers the professional experience and track record that clients demand. Through prosecuting cases on the federal and state levels, Kaplan Fox has successfully shaped the law through winning many important decisions on behalf of our clients. For more information about Kaplan Fox & Kilsheimer LLP, you may visit our website at www.kaplanfox.com.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
If you have any questions about this investigation, please contact:
CONTACT:
Pamela A. Mayer
KAPLAN FOX & KILSHEIMER LLP
800 Third Avenue, 38th Floor
New York, New York 10022
(646) 315-9003
[email protected]
Laurence D. King
KAPLAN FOX & KILSHEIMER LLP
1999 Harrison Street, Suite 1560
Oakland, California 94612
(415) 772-4704
[email protected]
Contacting or submitting information to Kaplan Fox & Kilsheimer LLP does not create an attorney-client relationship, nor an obligation on the part of Kaplan Fox to retain you as a client.
https://www.kaplanfox.com/case/icu-medical-inc/
View the original release on www.newmediawire.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
26 minutes ago
- Business Insider
‘Nothing Lasts Forever,' Says Top Investor About Palantir Stock
Palantir (NASDAQ:PLTR) stock presents investors with quite a quandary. Confident Investing Starts Here: On the one hand, there is no denying that the company has delivered incredible growth over the past few years. Its revenues are skyrocketing, its margins are strong, and its list of customers continues to grow by leaps and bounds. Its share price has responded in kind, surging by over 466% over the past twelve months. And therein lies the rub, as PLTR is now trading at elevated multiples that are far and above the sector average. This leads to the question of whether all that company growth has led to enthusiasm that is a bit too optimistic. Top investor Riyado Sofian is decidedly on the fence, and is not sure which way the winds will blow. 'It's hard to decide whether to buy or sell — best to just hold it,' states the 5-star investor, who is in the top 3% of TipRanks' stock pros. Sofian outlines the bull case, describing a company that has introduced game-changing AI technology that sets the firm apart from its peers. Beyond the growing sales, profits, and customers, the investor also points out that revenues from Palantir's top 20 customers increased by 26% year-over-year, a strong indication of customer satisfaction. While the company continues to raise its guidance, it often succeeds in going well beyond these numbers, notes Sofian, and it has repeatedly 'destroyed its guidance' in previous quarters. In other words, more massive growth could be on the horizon for Palantir. 'All things considered, this is execution on an elite level — there's no denying it,' adds Sofian. And yet, judging by traditional metrics, the company is overvalued, the investor acknowledges, and its narrative as 'the most important AI company in the West' is what has powered its continuing ascent. For that reason, as long as the company's growth continues apace, PLTR should continue to rise as well. However, that is far from certain, and at a valuation of 100x its revenues, there is practically no room for error if the impressive rate starts to slow. To this point, Sofian reminds investors that nothing lasts forever. With neither a Buy nor a Sell looking particularly appealing, Sofian is splitting the difference and rating PLTR shares a Hold (i.e. Neutral). (To watch Sofian's track record, click here) That stance is echoed across Wall Street. Of the 18 analyst reviews on file, 11 say Hold, while just 3 recommend Buy and 4 suggest Sell, making PLTR a consensus Hold. The average 12-month price target sits at $101.06, implying a ~23% downside from current levels. (See PLTR stock forecast) To find good ideas for AI stocks trading at attractive valuations, visit TipRanks' Best Stocks to Buy, a tool that unites all of TipRanks' equity insights.
Yahoo
an hour ago
- Yahoo
VinFast Auto Ltd (VFS) Q1 2025 Earnings Call Highlights: Record Deliveries Amid Financial Challenges
Net Revenue: USD657 million, a 150% increase year-over-year. Cost of Goods Sold: USD888 million, a 113% increase year-over-year. Gross Margin: Minus 35%, improved from minus 59% last year. SG&A Expenses: USD51 million, a 23% increase year-over-year. R&D Expenses: USD81 million, down 22% year-over-year. EBITDA: Minus USD396 million, with an EBITDA margin of minus 60%. Net Loss: Minus USD712 million, with a net loss margin of minus 109%. CapEx: USD147 million, down 24% year-over-year. Operating Cash Flow: Minus USD607 million. Liquidity: USD2.4 billion, including loans and grants. EV Deliveries: 36,330 vehicles, a 296% increase year-over-year. Two-Wheeler Deliveries: 44,904 units, a 473% increase year-over-year. Warning! GuruFocus has detected 4 Warning Signs with VFS. Release Date: June 09, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. VinFast Auto Ltd (NASDAQ:VFS) reported a significant increase in vehicle deliveries, with a 296% year-over-year growth in electric vehicle deliveries for Q1 2025. The company achieved a notable improvement in gross margin, moving from minus 59% in the same period last year to minus 35% in Q1 2025. VinFast is expanding its market presence in Southeast Asia, with strong growth in Vietnam and strategic partnerships in Indonesia and the Philippines. The company is investing in new vehicle platforms and E/E architecture to drive cost efficiencies and improve product offerings. VinFast has secured substantial financial support, with liquidity standing at approximately USD2.4 billion, including loans and grants from Vingroup and its founder. Despite improvements, VinFast Auto Ltd (NASDAQ:VFS) reported a net loss of USD712 million for Q1 2025, highlighting ongoing financial challenges. The company is facing a decline in quarter-over-quarter vehicle deliveries, with a 32% drop in electric vehicle deliveries compared to the previous quarter. VinFast is closing direct-to-consumer showrooms in North America and Europe, indicating potential challenges in these markets. The company recorded a USD20 million impairment charge related to the closure of showrooms, with expectations of additional charges in the coming quarters. VinFast's cost of goods sold remains high, at 135% of revenue for the quarter, indicating ongoing pressure on profitability. Q: Can you provide the timeline for the new factories in Vietnam, India, and Indonesia, and their impact on production capacity? A: All facilities in Asia are expected to start operations this year. The India factory will open in July, followed by Hai Phong and then Indonesia. These facilities will focus on more affordable models, while the existing Vietnam facility will handle high-end models. Q: What are the key catalysts for VinFast's growth in the coming years? A: VinFast is focusing on scaling operations, accelerating product development, and executing cost optimization. We aim to double vehicle deliveries in 2025 and maintain momentum into 2026, driven by deeper market penetration and new CKD manufacturing facilities. Our next-generation products will be more cost-effective, and 2025 is a foundational investment year for our platforms and zonal architecture. Q: Could you elaborate on the decision to pivot into the bus market and the expected timeline for bus deliveries? A: We have started delivering buses in Vietnam and expect to deliver around 1,000 this year. We are expanding into other markets like Indonesia, Europe, the Middle East, and the US, gradually capturing growth in electric bus penetration. Q: What is the expected trajectory of average selling prices (ASPs) for the rest of the year? A: The ASP for Q1 2025 was around USD15,000, similar to Q4 2024. For the full year 2025, ASP is likely to remain under USD20,000, with smaller models like VF 3 and VF 5 contributing significantly to deliveries. Q: Can you share more details on the new vehicle platform and E/E architecture? A: Our next-generation vehicle platform focuses on cost efficiency, commonality, and modularity. The new E/E architecture reduces wiring complexity and enhances software scalability. We are also redesigning top hats to align with the platform, reducing costs and improving manufacturing efficiency. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
2 hours ago
- Business Insider
‘Time to Take a Pause,' Says Investor About Nvidia Stock
Nvidia (NASDAQ:NVDA) stock has roared back to life over the past two months, following a decidedly uncharacteristic drop earlier in the year. Shares have now climbed roughly 50% since hitting a post-Liberation Day low, driven by easing trade tensions, strong AI demand, and another impressive earnings report last month. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter That rebound comes despite several headwinds earlier in the year. The U.S.-China trade spat and fears of a broader pullback in AI-related capital expenditures had weighed heavily on investor sentiment. In particular, a targeted export restriction from the Trump administration on Nvidia's H20 GPUs resulted in a $4.5 billion hit during the last quarter. Still, it is hard to argue with Nvidia's stellar performance during Q1 Fiscal 2026, during which the company delivered record revenues of $44 billion, a year-over-year surge of 69%. The all-important data center segment grew at an even faster clip of 73%. While acknowledging the healthy earnings and NVDA's recovering share price, investor Johnny Zhang is not convinced that all the geopolitical hiccups are in the rearview mirror. 'I believe the 2H 2025 could bring more uncertainty, as the lagging effects of Trump's tariff policy and any setbacks on potential deals with China could create new volatility in the market,' explains the investor. Those concerns are not just theoretical. Zhang points to the unresolved H20 issue, stemming from U.S. export restrictions, as a key example. Nvidia is now expected to take an $8 billion inventory write-off as a result, and its margins are likely to decline further on a sequential basis. More broadly, the company has acknowledged it could forfeit access to a $50 billion total addressable market in China if those restrictions remain in place. Moreover, while Zhang believes that Nvidia will be able to navigate any economic slowdowns, the investor thinks there is a high possibility that the impact of the Trump tariffs will be felt during the latter part of the year. Against that backdrop, Zhang emphasizes that the recent rally in Nvidia's stock may not be sustainable without renewed visibility. He notes that further upside will hinge largely on AI spending trends in 2026, an outlook he calls 'highly uncertain.' In short, while Nvidia's fundamentals remain strong, its near-term growth path is anything but guaranteed. 'Chasing the stock's rally from here seems less compelling to me,' concludes Zhang, who gives NVDA a Hold (i.e. Neutral) rating. (To watch Zhang's track record, click here) Wall Street has a decidedly rosier view of NVDA. With 35 Buy, 4 Hold, and 1 Sell recommendations, NVDA continues to enjoy a Strong Buy consensus rating. Its 12-month average price target of $172.36 implies an upside north of 20%. (See )
